Plain-English translation of NCT05772208 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding or —two newer immunotherapy drugs—to standard cancer treatment works better than standard treatment alone for advanced nasopharyngeal cancer. You qualify if your cancer shows a specific warning sign (detectable EBV DNA) even after your first round of chemotherapy. The study will randomly assign you to receive either standard treatment plus , standard treatment plus , or standard treatment alone.
Patients whose cancer shows this particular warning sign tend to have worse outcomes with standard treatment alone. Researchers believe adding one of these immunotherapy medications may help fight the cancer more effectively in these higher-risk patients.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive two more cycles of chemotherapy (the second and third rounds) combined with your assigned treatment—either , , or neither. After that, you'll receive radiation therapy combined with a single chemotherapy drug. Depending on your treatment group, you may continue receiving the immunotherapy medication for several months after radiation ends. You'll have regular clinic visits, blood tests, and imaging scans to monitor how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China